Aptevo Therapeutics Inc. Annual Report - How They Did This Year

I’m putting together a guide to help you understand Aptevo Therapeutics’ performance over the past year. My goal is to break down their complex filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Aptevo is a Seattle-based biotech company focused on immunotherapy. They design drugs that help your immune system recognize and kill cancer cells. They don't have products on pharmacy shelves yet; instead, they operate like a high-tech laboratory.

They use their "ADAPTIR" and "ADAPTIR-FLEX" platforms to build specialized antibodies. Think of these as smart-guided missiles. They grab a cancer cell with one hand and a fighter T-cell with the other, forcing your body to attack the tumor. They focus on blood cancers and solid tumors, using protein engineering to make their drugs more potent and longer-lasting than traditional treatments.

2. Major wins and the pipeline

The company is currently focused on two main clinical candidates:

• Mipletamig (for Leukemia): This is their lead drug. Recent data is promising: 86% of patients saw a clinical benefit, and 79% achieved some form of remission. Most importantly, they’ve seen zero cases of dangerous inflammation in these patients. This is a major safety advantage. They expect the "RAINIER" trial to finish in late 2026.
• ALG.APV-527 (for Solid Tumors): This drug targets tumors found in breast, lung, and prostate cancers. In early testing, 59% of patients saw their disease stabilize. The company is currently testing different doses to prepare for a larger Phase 2 study.
• The "Bench": They have other early-stage drugs in the works. These use "trispecific" designs to target tumors more precisely, activating the immune system only when a tumor is present to reduce toxic side effects.

3. Financial performance and health

Aptevo is in a "cash-burn" phase. For 2024, the company reported a loss of $35.2 million, compared to $42.1 million in 2023. They aren't making a profit yet and spend about 65% of operating costs on research and development. As of late 2025, the company’s market value is about $9.8 million, and they hold $12.4 million in cash.

Because they have no revenue from drug sales, they fund operations by selling new shares of stock. Every time they do this, more shares are issued, which reduces your ownership percentage. They have agreements in place to sell stock whenever they need cash to keep the company running, which can put downward pressure on the share price.

4. Key risks

• Survival: The company depends entirely on raising money and successful clinical trials. With a short cash runway, they are constantly looking for new capital.
• Dilution: Frequent stock sales to fund research can lower the value of your existing shares. The share count has grown significantly over the last two years.
• Clinical Failure: Biotech is "all or nothing." If a trial fails, the company’s value could drop significantly because their pipeline is small.
• Competition: They compete against massive pharmaceutical giants with much deeper pockets.
• Nasdaq Compliance: With a tiny market value and a low share price, they risk being delisted from the stock exchange, which would make it harder to trade the stock and raise money.

Is this right for you?

Investing in Aptevo is a high-risk, high-reward play. You are essentially betting on the success of their clinical trials and their ability to manage their cash until they reach a breakthrough. If you are looking for steady dividends or established revenue, this is likely not the right fit. However, if you have a high risk tolerance and believe in the potential of their "smart-guided" antibody technology, it is a company to watch as they move toward their 2026 trial milestones.